U.S. DIETARY GUIDELINES AND HEALTHY BODY WEIGHT
Location: Obesity and Metabolism Research Unit
Title: Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
| Hanley, Michael - AMYLIN PHARMACEUTICALS |
| Mack, Christine - AMYLIN PHARMACEUTICALS |
| Parkes, David - AMYLIN PHARMACEUTICALS |
| Young, Andrew - AMYLIN PHARMACEUTICALS |
Submitted to: Invention Report
Publication Type: Other
Publication Acceptance Date: May 10, 2006
Publication Date: October 5, 2006
Citation: Laugero, K.D., Hanley, M., Mack, C.M., Parkes, D.G., Young, A.A. 2006. Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders. Invention Report. 2006. Patent PCT Publication No.WO 2006/105527.
Interpretive Summary: It has now been discovered that amylin, amylin agonists, amylin analogs, amylin agonist analogs, amylin derivatives, or a combination thereof, may be able to modulate the stress systems and/or the actions of CRF and/or glucocorticoids (GC), thereby presenting novel pharmacotherapeutic options. As demonstrated herein, amylin administration appears to reduce or protect against stress and it effects (e.g., anxiety, obsessive-compulsive behavior, depression, psychosis, changes in eating behavior). We also demonstrate herein that, in specific animal behavioral tests, amylin administration results in behavioral effects that include anti-stress, anxiolytic, antidepressant, and antipsychotic actions.
Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.